Physician
Internal Medicine
Dr. Pedro L. Farinha, MD
|
|
Give Review
Pedro Farinha practices Internal Medicine. Pedro Farinha is a published physician. He has 31 papers published. The most current publication "Spinal epidural hematoma associated with warfarin therapy." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
- Macrophages predict treatment outcome in Hodgkin''s lymphoma.
- The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
- Vascularization predicts overall survival and risk of transformation in follicular lymphoma.
- Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome.
- Prognostic factors in follicular lymphoma.
- Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
- Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.
- The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.
- Transformation of a cutaneous follicle center lymphoma to a diffuse large B-cell lymphoma-an unusual presentation.
- Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
- Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.
- MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
- The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
- Impact of whole genome amplification on analysis of copy number variants.
- Sequential transcription factor targeting for diffuse large B-cell lymphomas.
- Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
- LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
- HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen.
- Predicting survival in follicular lymphoma using tissue microarrays.
- Cytogenetic abnormalities in MALT lymphomas and their precursor lesions from different organs. A fluorescence in situ hybridization (FISH) study.
- Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).
- Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma.
- Helicobacter pylori and MALT lymphoma.
- Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
- High frequency of MALT lymphoma in a series of 14 cases of primary breast lymphoma.
- Metastasizing hyalinizing spindle cell tumour with giant rosettes: report of a case with long survival.
- Oral lichen planus versus oral lichenoid eruption as a manifestation of contact allergy.
- Spinal epidural hematoma associated with warfarin therapy.
Schools
Rosalind Franklin University of Medicine and Science Chicago Medical School
University Of Minnesota
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
University of Minnesota -
Rosalind Franklin University of Medicine and Science
Drug Facts
| NPI NUMBER | 1033113006 | |
| NPPES Provider LastName | FARINHA | |
| NPPES Provider FirstName | PEDRO | |
| NPPES Provider ZIPCode | 935553168 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 4133.0 | |
| Distinct Opioid Count | 7.0 | |
| Opioid Claim Count | 336.0 | |
| Percent Opioid Claims | 8.13 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1033113006 |
| Last Name Of The Provider | FARINHA |
| First Name Of The Provider | PEDRO |
| View All |
Similar Doctors
|
|
Dr. Robert M. Schumacher, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence N. Cosner Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vernon H. Shull, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas E. Roberts Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cornelis Vanderhoek, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amikjit S. Reen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kain Kumar, MD
This Doctor is OpenDoctor Recommended.
|